Pre-made Flanvotumab benchmark antibody ( Whole mAb, anti-TYRP1 therapeutic antibody, Anti-TRP/CAS2/CATB/GP75/OCA3/TRP1/TYRP/b-PROTEIN Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Flanvotumab biosimilar, Whole mAb, Anti-TYRP1 Antibody: Anti-TRP/CAS2/CATB/GP75/OCA3/TRP1/TYRP/b-PROTEIN therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma. It targets TYRP1.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-216-1mg	1mg	3090
GMP-Bios-ab-216-10mg	10mg	Inquiry
GMP-Bios-ab-216-100mg	100mg	Inquiry
GMP-Bios-ab-216-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Flanvotumab biosimilar, Whole mAb, Anti-TYRP1 Antibody: Anti-TRP/CAS2/CATB/GP75/OCA3/TRP1/TYRP/b-PROTEIN therapeutic antibody
INN Name	Flanvotumab
Target	TYRP1
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2011
Year Recommended	2012
Companies	ImClone Systems;Eli Lilly
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Malignant melanoma
Development Tech	na